Sonic Healthcare Limited
Sonic Healthcare Limited (SKHCF) Financial Performance & Income Statement Overview
Review Sonic Healthcare Limited (SKHCF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Sonic Healthcare Limited (SKHCF) Income Statement & Financial Overview
Review Sonic Healthcare Limited SKHCF income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $4.66B | $4.27B | $3.94B | $2.04B |
| Cost of Revenue | $3.11B | $3.20B | $2.97B | $1.35B |
| Gross Profit | $1.56B | $1.07B | $964.78M | $690.33M |
| Gross Profit Ratio | $0.33 | $0.25 | $0.25 | $0.34 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $127.27M | $735.71M | $673.90M | $54.76M |
| Operating Expenses | $127.27M | $735.71M | $673.90M | $470.72M |
| Total Costs & Expenses | $3.23B | $3.94B | $3.65B | $1.82B |
| Interest Income | $12.30M | $12.46M | $9.20M | $22.47M |
| Interest Expense | $85.94M | $65.41M | $44.94M | $0.00 |
| Depreciation & Amortization | $393.64M | $383.66M | $357.31M | $178.66M |
| EBITDA | $910.18M | $749.12M | $648.19M | $398.71M |
| EBITDA Ratio | $0.20 | $0.17 | $0.16 | $0.20 |
| Operating Income | $1.43B | $333.51M | $290.88M | $220.05M |
| Operating Income Ratio | $0.31 | $0.08 | $0.07 | $0.11 |
| Other Income/Expenses (Net) | -$998.30M | -$33.46M | -$93.74M | -$438.43M |
| Income Before Tax | $430.60M | $300.05M | $394.28M | $197.14M |
| Income Before Tax Ratio | $0.09 | $0.07 | $0.10 | $0.10 |
| Income Tax Expense | $104.93M | $81.91M | $78.63M | $39.32M |
| Net Income | $308.78M | $202.31M | $302.63M | $151.31M |
| Net Income Ratio | $0.07 | $0.05 | $0.08 | $0.07 |
| EPS | $0.65 | $0.43 | $0.65 | $0.32 |
| Diluted EPS | $0.65 | $0.43 | $0.64 | $0.32 |
| Weighted Avg Shares Outstanding | $476.10M | $473.43M | $469.08M | $472.22M |
| Weighted Avg Shares Outstanding (Diluted) | $476.99M | $474.71M | $471.98M | $472.08M |
Over the past four quarters, Sonic Healthcare Limited demonstrated steady revenue growth, increasing from $2.04B in Q3 2023 to $4.66B in Q4 2024. Operating income reached $1.43B in Q4 2024, maintaining a consistent 31% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $910.18M, reflecting operational efficiency. Net income rose to $308.78M, with EPS at $0.65. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan